Effects of multidose simvastatin co-administration on pharmacokinetic profile of apatinib in rats by UPLC-MS/MS

Abstract

1. Apatinib, a small molecule anti-angiogenic tyrosine kinase inhibitor is used extensively to treat advanced gastric cancer and simvastatin (SV) is often co-prescribed to treat cardiovascular disease in cancer patients. As both apatinib and SV are metabolized primarily by cytochrome P450 variant CYP3A4, they are likely to interact. Therefore, the potential effect of SV co-administration on pharmacokinetics of apatinib in Sprague-Dawley male rats is demonstrated for the first time.

2. Sixteen rats were randomly divided into two groups (n = 8), 2 mg/kg SV orally co-administrated for seven days (group B) and the corresponding control group (group A). Apatinib concentrations of rat plasma samples were detected by ultra-performance liquid chromatography tandem mass spectrometry. Pharmacokinetic parameters were calculated using non compartmental methods.

3. Co-administration of SV for seven days significantly increased area under curve (AUC_(0-t)), AUC_(0-∞) and maximum plasma concentration of apatinib by 2.4-, 2.4-, and 2.7-fold, respectively while decreasing apparent volume of distribution and clearance by 81.7 and 73.9%, respectively.

4. These findings suggest that concomitant administration of SV with 7 days may have inhibited the metabolism of apatinib in rats.

Keywords:

• Apatinib
• simvastatin
• cytochrome P450
• drug-drug interaction
• pharmacokinetic profile

Disclosure statement

The authors of this manuscript declare no conflict of interest.

Additional information

Funding

This work was supported by National Science and Technology Major Project for Major New Drugs Innovation and Development 2020 in China under Grant number 2020ZX09201006.